Related references
Note: Only part of the references are listed.Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non-Small-Cell Lung Cancer
Martin J. Edelman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
Stephen Yip et al.
JOURNAL OF PATHOLOGY (2012)
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas
Arthur P. Chou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes
David Capper et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
IDH mutations in glioma and acute myeloid leukemia
Lenny Dang et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
et al.
NEUROSURGERY (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas
Matthew J. McGirt et al.
NEUROSURGERY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)